Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Cybin Inc (CYBN)

Cybin Inc (CYBN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

BIIB : 292.15 (+0.23%)
ESALY : 71.3000 (+1.29%)
ATAI : 3.18 (+0.63%)
SAGE : 40.64 (-2.33%)
ARKK : 34.35 (-0.78%)
SEEL : 1.0700 (-6.96%)
CMPS : 10.91 (+5.61%)
MNMD : 2.82 (+1.44%)
CYBN : 0.3224 (-4.42%)
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced that the Company presented...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Business Highlights

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept....

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced that the Company presented...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today reported unaudited financial...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END

CYBN.NE : 0.430 (-2.27%)
MRVL.VN : 0.150 (+7.14%)
SAGE : 40.64 (-2.33%)
NERV : 3.04 (+1.67%)
ATAI : 3.18 (+0.63%)
CYBN : 0.3224 (-4.42%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to...

MRVL.VN : 0.150 (+7.14%)
SAGE : 40.64 (-2.33%)
NERV : 3.04 (+1.67%)
ATAI : 3.18 (+0.63%)
CYBN : 0.3224 (-4.42%)
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to announce that its...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Schedule for Upcoming Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to announce its participation...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)

Barchart Exclusives

The Gold Bugs are Starting to Stir
If you listen carefully, you can hear the gold bugs beginning to chatter about higher gold prices. And this time, they may be correct. But have a little patience before loading the boat with gold products. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar